Información del artículo
Resumen
El tratamiento de la diabetes mellitus tipo 2 requiere de un control global de los múltiples factores de riesgo que suelen asociarse en estos pacientes. Entre ellos, la disminución de la tasa de hipoglucemias y el tratamiento de la obesidad, especialmente de predominio central, son muy importantes. Por este motivo, dentro de los variados enfoques fisiopatológicos para mejorar el control glucémico que no incluyen la insulina, los fármacos que no producen aumento en la tasa de hipoglucemias ni aumento de peso tienen un atractivo añadido. Así, los nuevos antidiabéticos orales basados en potenciar el efecto incretínico destacan por ser capaces de producir pérdidas moderadas de masa corporal. Además, la seguridad es un factor que hay que tener en cuenta en pacientes que estarán expuestos a estos fármacos durante décadas no sólo por evitar efectos adversos graves, lo cual es fundamental, sino también para tratar de garantizar el cumplimiento terapéutico a largo plazo.
Palabras clave:
Antidiabéticos orales/terapias/fármacos
Seguridad
Tolerabilidad
Diabetes mellitus tipo 2
Tratamiento
Abstract
The treatment of type 2 diabetes mellitus requires overall control of the multiple risk factors usually found in these patients. Amongst these, avoidance of hypoglycemia and treatment of obesity, especially central obesity, is of utmost importance. Consequently, among the various physiopathological approaches to improve glycemic control that do not include insulin, drugs that are not associated with increased risk of hypoglycaemia or increase weight are of special interest. Hence, the new incretin-based oral antidiabetes drugs are of great relevance, given their weight neutrality and very low risk of hypoglycaemia. Safety is clearly a factor to be considered in patients who will be exposed to these drugs for decades, not only to avoid severe adverse effects –which is essential– but also to guarantee long-term compliance.
Keywords:
Oral antidiabetes agentes/therapies/drugs
Safety
Tolerability
Type 2 diabetes mellitus
Treatment
El Texto completo está disponible en PDF
Bibliografía
[1.]
D.L. Wingard, E.L. Barrett-Connor, A. Ferrara.
Is insulin really a heart disease risk factor?.
Diabetes Care, 18 (1995), pp. 1299-1304
[2.]
P.A. Wolf, R.B. D’Agostino, A.J. Belanger, W.B. Kannel.
Probability of stroke: a risk profile from the Framingham study.
Stroke, 22 (1991), pp. 312-318
[3.]
US Renal Data System.
Annual Data Report.
National Institute of Health, (2003),
[4.]
J.A. Beckman, M.A. Creager, P. Lobby.
Diabetes and atherosclerosis: epidemiology, pathophysiology and management.
J Am Med Assoc, 287 (2002), pp. 2570-2581
[5.]
L. Zhou, W. Deng, P. Fang, D. He, W. Zhang, K. Liu, et al.
Prevalence, incidence and risk factors of chronic heart failure in the type 2 diabetic population: systematic review.
Curr Diabetes Rev, 5 (2009), pp. 171-184
[6.]
P. Pedrianes, P.L. De Pablos.
La adiponectina y el riesgo de enfermedad coronaria.
Revista Española de Obesidad, 7 (2008), pp. 73-79
[7.]
R.R. Holman, S.K. Paul, M.A. Bethel, D.R. Matthews, H.A.W. Neil.
10-Year follow-up of intensive glucose control in type 2 diabetes.
N Engl J Med, 359 (2008), pp. 1577-1589
[8.]
Action to control cardiovascular risk in diabetes (ACCORD) study group.
Effects of intensive glucose lowering in type 2 diabetes.
N Engl J Med, 358 (2008), pp. 2545-2559
[9.]
Action in diabetes and vascular disease: preterax and diamicron modified release controlled evaluation (ADVANCE) collaborative group.
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
N Engl J Med, 358 (2008), pp. 2560-2572
[10.]
S. Fullert, F. Schenider, E. Haak, H. Rau, K. Badenhoop, G. Lubben, et al.
Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study.
J Clin Endocrinol Metab, 87 (2002), pp. 5503-5506
[11.]
D.J. Juurlink, T. Gomes, L.L. Lipscombe, P.C. Austin, J.E. Hux, M.M. Mamdani.
Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study.
BMJ, 339 (2009), pp. b2942
[12.]
UK Prospective Diabetes Study Group.
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).
Lancet, 352 (1998), pp. 854-865
[13.]
R.A. DeFronzo, T.G. Duncan.
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus.
N Engl J Med, 333 (1995), pp. 541-549
[14.]
American Diabetes Association and European Association for the Study of Diabetes consensus statement.
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy.
Diabetes Care January, 32 (2009), pp. 193-203
[15.]
I.W. Campbell, H.C. Howlett.
Worldwide experience of metformin as an effective glucose-lowering agent: a metaanalysis.
Diabetes Metab Rev, 11 (1995), pp. S57-S62
[16.]
F.X. Pi-Suñer.
The effects of pharmacologic agents for type 2 diabetes mellitus on body weight.
Postgrad Med, 120 (2008), pp. 5-17
[17.]
B.F. Clarke, I.W. Campbell.
Comparison of metformin and chlorpropamide in non-obese, maturity-onset diabetic uncontrolled with diet.
BMJ, 2 (1977), pp. 1576-1578
[18.]
American Diabetes Association and European Association for the Study of Diabetes consensus statement.
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy.
Daiebetes Care, 31 (2008), pp. 1-11
[19.]
S. Bolen, L. Feldman, J. Vassy, L. Wilson, H.C. Yeh, S. Marinopoulos, et al.
Sysyematic Review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus.
Ann Intern Med, 147 (2007), pp. 386-399
[20.]
J.B. Brown, K. Peula, J. Barzilay, M.K. Herson, P. Latare.
Lactic acidosis rates in type 2 diabetes.
Diabetes Care, 21 (1998), pp. 1659-1663
[21.]
D.T. Eurich, F.A. McAlister, D.F. Blackburn, S.R. Majumdar, R.T. Tsuyuki, J. Varney, et al.
Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review.
BMJ, 335 (2007), pp. 497-507
[22.]
H.E. Lebovitz.
Joslin’s diabetes mellitus: tratamiento de la hiperglucemia con antidiabéticos orales en la diabetes mellitus tipo 2.
14.a ed., Lippincot, Williams & Wilkins, (2005),
[23.]
H.E. Lebovitz, A. Melander.
International book of diabetes mellitus: sulfonylureas: basic apects and clinical use.
3rd ed., John Wiley & Sons Ltd., (2004),
[24.]
J. Belsey, G. Krishnarajah.
Glycaemic control and adverse events in patients withtype 2 diabetes treated with metformin plus sulphonylurea: a meta-analysis.
Diabetes Obes Metab, 10 (2008), pp. 1-7
[25.]
C.V. Asche, C. McAdam-Marx, L. Shane-McWorther, X. Sheng, C.A. Plauschinat.
Association between oral antidiabetic use, adverse events and outcomes in patientes with type 2 diabetes.
Diabetes Obes Metab, 10 (2008), pp. 638-645
[26.]
S.E. Kahn, S.M. Haffner, M.A. Heise, W.H. Herman, R.R. Holman, N.P. Jones, ADOPT Study Group, et al.
Glycemic durability of rosiglitazone, metformin or glyburide monotherapy.
N Engl J Med, 355 (2006), pp. 2427-2443
[27.]
A. Barnett, J. Allsworth, K. Jameson, R. Mann.
A review of the effetcs of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies.
Curr Med Res Opin, 23 (2007), pp. 1493-1507
[28.]
T.P. Ciaraldi, A.P.S. Kong, N.V. Chu, D.D. Kim, S. Baxi, M. Loviscach, et al.
Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects.
Diabetes, 51 (2002), pp. 30-36
[29.]
A.M. Lincoff, K. Wolski, S.J. Nicholls, S.E. Nissen.
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. A meta-analysis of randomized trials.
JAMA, 298 (2007), pp. 1180-1188
[30.]
J. Dormandy, B. Charbonnel, D.J. Eckland.
Secondary prevention of macrovascular events in patiens with type 2 diabetes in the PROACTIVE study (prospective pioglitazone clinical trial in macrovascular events): a randomised controlled trial.
Lancet, 366 (2005), pp. 1279-1289
[31.]
The DREAM (diabetes reduction assessment with ramipril and rosiglitazone medication) trial investigators.
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.
Lancet, 368 (2006), pp. 1096-1105
[32.]
S. Rosenblatt, B. Miskin, N.B. Glazer, M.J. Prince, K.E. Robertson, For the piglitazone 026 study group.
The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
Coron Artery Dis, 12 (2001), pp. 413-423
[33.]
S. Mudaliar, R.R. Henry.
International book of diabetes mellitus: thiazolidinediones as PPAR agonists.
3rd ed., John Wiley & Sons Ltd., (2004),
[34.]
E.R. Higgs, A.J. Krentz, On behalf of the association of British clinical endocrinologists.
ABCD position statement on glitazones.
Prac Diab Int, 24 (2004), pp. 1-3
[35.]
S.E. Nissen, K. Wolski.
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
N Engl J Med, 356 (2007), pp. 2457-2471
[36.]
P.D. Home, S.J. Pocock, H. Beck-Nielsen, P.S. Curtis, R. Gomis, M. Hanefeld, For the RECORD Study Team, et al.
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.
Lancet, 373 (2009), pp. 2125-2135
[37.]
S. Aronoff, S. Rosenblatt, S. Braithwaite, J.W. Egan, A.I. Mathisen, R.I. Schneider.
Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes. A 6-month randomized placebo-controlled dose-response study.
Diabetes Care, 23 (2000), pp. 1605-1611
[38.]
W.J. Malaisse.
Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus.
Treat Endocrinol, 2 (2003), pp. 401-414
[39.]
M.J. Davies, S. Chatterjee.
International book of diabetes mellitus: Meglitinides: basic aspects and clinical uses.
3rd ed., John Wiley & Sons Ltd., (2004),
[40.]
G. Xu, D.A. Stoffers, J.F. Habener, S. Bonner-Weir.
Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increasing β-cell mass and improved glucose tolerance in diabetic rats.
Diabetes, 48 (1999), pp. 2270-2276
[41.]
M.A. Nauck, F. Stockman, R. Ebert, W. Creutzfeldt.
Reduced incretin effect in type 2 (non-insulin dependent) diabetes.
Diabetologia, 29 (1986), pp. 46-52
[42.]
S.A. Miller, E.L. St. Onge.
Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Ann Pharmacother, 40 (2006), pp. 1336-1343
[43.]
C.A. Abbott, E. Baker, G.R. Sutherland, G.W. McCaughan.
Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene.
Inmunogenetics, 40 (1994), pp. 331-338
[44.]
O.J. Phung, J.M. Scholle, M. Talwar, C.I. Coleman.
Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.
JAMA, 303 (2010), pp. 1410-1418
[45.]
G. Herman, M. Hanefeld, M. Wu, X. Chen, P. Zhao, P. Stein.
Effect of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor on glycaemic control after 12 weeks in patients with type 2 diabetes.
Diabetes, 54 (2005), pp. A134
[46.]
Novartis Galvus, a new oral treatment for type 2 diabetes, receives positive opinion following vhanges to european prescribing information. 2008 [consultado 14-1-2008]. Disponible en: http://hugin.info/134323/R/1176484/233550.pdf
[47.]
J.J. Holst, C.F. Deacon.
Role of GLP-1 analogues and DPP-IV inhibitors in the treatment of type 2 diabetes.
Avances en Diabetología, 22 (2006), pp. 115-125
[48.]
Knudsen LB, Nielsen PF, Huusfeldt PO. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once-daily administration. J Med Chem. 200;43:1664–9.
[49.]
D.J. Drucker, M.A. Nauck.
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Lancet, 368 (2006), pp. 1696-1705
[50.]
S.E. Inzucchi, D.K. McGuire.
New drugs for the treatment of diabetes. Part II: Incretin-based therapy and beyond.
Circulation, 117 (2008), pp. 441-450
[51.]
R.A. DeFronzo, R.E. Ratner, J. Han, D.D. Kim, M.S. Fineman, A.D. Baron.
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformintreated patients with type 2 diabetes.
Diabetes Care, 28 (2005), pp. 1092-1100
[52.]
E. Wajcberg, A. Tavaria.
Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus.
Expert Opin Pharmacother, 10 (2009), pp. 135-142
[53.]
M. Puig, C. Fernández, S. Rueda.
Diabetomecum 2008: terapia basada en incretinas: análogos de GLP-1, incretina miméticos e inhibidores de DPP-IV.
Publicaciones Pemanyer, (2008),
[54.]
R. Rabasa-Lhoret, J.L. Chiasson.
International book of diabetes mellitus: α-glucosidase inhibitors.
3rd ed., John Wiley & Sons Ltd., (2004),
[55.]
J.L. Chiasson, R.G. Josse, R. Gomis, M. Hanefeld, A. Karasik, M. Laakso.
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.
Lancet, 359 (2002), pp. 2072-2077
[56.]
A.J. Garber.
International book of diabetes mellitus: metformin and other biguanides: pharmacology and therapeutic usage.
3rd ed., John Wiley & Sons Ltd., (2004),
[57.]
G. Bakris, G. Viberti, W.M. Weston, M. Heise, L.E. Porter, M.I. Freed.
Rosiglitazone reduces urinary albumin excretion in type II diabetes.
J Human Hypertens, 17 (2003), pp. 7-12
[58.]
M.A. Mughal, M.Y. Memon, M.K. Zardari, R.K. Tanwani, M. Ali.
Effect of acarbose on glycemic control, serum lipids and lipoproteins in type 2 diabetes.
J Pak Med Assoc, 2 (2000), pp. 33-38
Copyright © 2010. Elsevier España S.L.. Todos los derechos reservados
